Loading
institutionsInstitution
Masonic Cancer Center, University of Minnesota
The Masonic Cancer Center is where Robert Good performed the first successful human bone marrow transplant in 1968; today Jeffrey Miller's group runs natural killer cell therapy trials, and Stephen Hecht's laboratory defined the tobacco-specific carcinogens used in tobacco regulation.
Overview
NCI comprehensive since 1998, the Masonic Cancer Center inherits the University of Minnesota's transplant legacy: Robert Good performed the first successful human bone marrow transplant here in 1968, and John Wagner's group pioneered unrelated cord blood transplantation. Jeffrey Miller's programme ran the first haploidentical natural killer cell infusions in leukaemia and now partners with Fate Therapeutics on iPSC-derived NK products; Daniel Vallera's tri-specific killer engagers extend the NK concept. Stephen Hecht's laboratory defined the tobacco-specific carcinogens and biomarkers used in tobacco regulation. Clinical care is delivered through M Health Fairview.
Location
Minneapolis, MN, US
Type
cancer center · University of Minnesota
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#130 · 35 points (0 Newsweek + 15 NCI + 20 from 10 linked objects) · ranking
- Transplant and cord blood
- NK cell therapy
- Tobacco carcinogenesis
Similar pages
- IdeaQualify one iPSC master cell bank once for many off-the-shelf cell products
Shares Fate Therapeutics, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- TargetCD7
Shares Allogeneic (off-the-shelf) cell therapy, Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TreatmentDorocubicel (UM171-expanded cord blood)
Shares Allogeneic (off-the-shelf) cell therapy, Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- CompanyONK Therapeutics
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- TreatmentAllogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
Shares Allogeneic (off-the-shelf) cell therapy, Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TechnologyNK cell therapy and CAR-NK
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Acute myeloid leukaemia.
- IdeaOff-the-shelf natural killer cells to sweep up residual disease
Shares Fate Therapeutics, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.